In preparation for a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC), the FDA has made public the interim results of phase 3 clinical trials for the Moderna COVID-19 vaccine candidate. This meeting will discuss the Emergency Use Authorisation (EUA) application and determine any recommendations for approval.

Phase 3 clinical trials for this vaccine were spread across 99 sites in the United States and participants were aged 18 years or older. The Moderna vaccine utilises a messenger RNA (mRNA) platform. Interim results show an acceptable safety profile. Following the administration of 2 doses, 28 days apart, it is reported that this vaccine has an efficacy rate of 94.5%.

To read the document in full please refer to the link below:

Vaccines and Related Biological Products Advisory Committee: FDA briefing document- Moderna COVID-19 vaccine